ORKA — Oruka Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $400.99m
- $28.27m
- 42
- 34
- 36
- 30
Annual income statement for Oruka Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 9.77 | 19.3 | 10.6 | 7.3 | 88.1 |
| Operating Profit | -9.77 | -19.3 | -10.6 | -7.3 | -88.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.75 | -19.3 | -9.93 | -5.34 | -83.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -9.74 | -19.3 | -9.93 | -5.34 | -83.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.74 | -19.3 | -9.93 | -5.34 | -83.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.74 | -19.3 | -9.93 | -5.34 | -83.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -24.8 | -16.7 | -8.27 | -4.44 | -4.99 |
| Special Dividends per Share |